Segment Information (Tables)

6 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Revenue by Segment and Reconciling Items

The table below presents a reconciliation of net revenues and net operating profit by reportable segments (in thousands):

	Three Months Ended December 31,				Six Months Ended December 31,
	2024		2023		2024		2023
Net revenue by segment
Sleep and Breathing Health	$	1,125,593	$	1,017,855	$	2,193,330	$	1,980,892
Residential Care Software	156,496		144,946		313,268		284,230
Total	$	1,282,089	$	1,162,801	$	2,506,598	$	2,265,122
Depreciation and amortization by segment
Sleep and Breathing Health	$	25,249	$	21,956	$	48,268	$	42,475
Residential Care Software	2,240		2,725		4,608		5,485
Amortization of acquired intangible assets and corporate assets	18,950		20,103		38,293		41,758
Total	$	46,439	$	44,784	$	91,169	$	89,718
Net operating profit by segment
Sleep and Breathing Health	$	488,721	$	409,141	$	949,696	$	783,879
Residential Care Software	48,882		41,787		96,503		73,091
Total	$	537,603	$	450,928	$	1,046,199	$	856,970
Reconciling items
Corporate costs	$	101,679	$	85,421	$	203,890	$	173,169
Amortization of acquired intangible assets	18,681		19,834		37,755		41,220
Restructuring expenses	—		64,228		—		64,228
Masks with magnets field safety notification expenses (1)	—		6,351		—		6,351
Astral field safety notification expenses (2)	—		—		—		7,911
Interest expense (income), net	775		13,805		2,436		28,762
(Gain) Loss attributable to equity method investments	(1,077)		(739)		(2,040)		3,156
Loss on equity investments	1,439		1,888		2,119		2,491
Other, net	(2,216)		686		219		(1,963)
Income before income taxes	$	418,322	$	259,454	$	801,820	$	531,645

(1)    The masks with magnets field safety notification expenses relate to estimated costs to provide alternative masks to patients in response to updated contraindications for use of masks that incorporate magnets.

(2)    The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019.